BANK VONTOBEL/PUT/GILEAD SCIENCES/52/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 14:03:49 2024-06-28 EDT | ||
| 0.039 EUR | -2.50% |
|
| 1 month | -57.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.039 | -2.50% |
| 24-06-27 | 0.04 | +5.26% |
| 24-06-26 | 0.038 | -.--% |
| 24-06-25 | 0.038 | +15.15% |
| 24-06-24 | 0.033 | -31.25% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 02:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VD45EN |
| ISIN | DE000VD45EN5 |
| Date issued | 2024-04-26 |
| Strike | 52 $ |
| Maturity | 2024-12-20 (173 Days) |
| Parity | 10 : 1 |
| Emission price | 0.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.13 € |
|---|---|
| Lowest since issue | 0.033 € |
| Spread | 0.01 € |
| Spread % | 19.23% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.61
USD
Average target price
82.97
USD
Spread / Average Target
+20.93%
- Stock Market
- Warrants
- Warrant
